ProKidneyPROK
PROK
About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Employees: 204
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
9.95% less ownership
Funds ownership: 37.05% [Q1] → 27.11% (-9.95%) [Q2]
21% less funds holding
Funds holding: 70 [Q1] → 55 (-15) [Q2]
41% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 34
51% less capital invested
Capital invested by funds: $42M [Q1] → $20.8M (-$21.2M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
58%
downside
Avg. target
$6.25
163%
upside
High target
$9
278%
upside
4 analyst ratings
3 positive
75%
0 neutral
0%
1 negative
25%
UBS Eliana Merle | 236%upside $8 | Buy Maintained | 15 Jul 2025 |
Guggenheim Vamil Divan | 194%upside $7 | Buy Maintained | 14 Jul 2025 |
Citigroup Yigal Nochomovitz | 278%upside $9 | Buy Maintained | 9 Jul 2025 |
B of A Securities Jason Gerberry | 58%downside $1 | Underperform Downgraded | 30 Jun 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2025, and provided regulatory and clinical updates.
Positive
The Motley Fool
1 month ago
Meet the Biotech Stock That Rocketed 775% Higher
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you crave. At the end of June, ProKidney (PROK 2.06%) stock was languishing at less than $1 per share.
Positive
Zacks Investment Research
1 month ago
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Zacks Investment Research
1 month ago
Best Momentum Stocks to Buy for July 17th
PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for July 17th
PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.
Positive
The Motley Fool
1 month ago
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion.
Biotech stocks can be risky but exciting investments because they can soar quickly on positive news, such as a drug approval or simply the hope that they may soon have an approved treatment. They can drop just as quickly on negative news.
Positive
Zacks Investment Research
1 month ago
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
1 month ago
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced confirmation of alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel. Rilparencel is an autologous cellular therapy that received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and currently is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy's potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
Positive
Zacks Investment Research
1 month ago
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
Positive
Yahoo Finance
1 month ago
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.
Charts implemented using Lightweight Charts™